Telomir Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
Telomir Pharmaceuticals, Inc. (Nasdaq: TELO), an emerging growth company incorporated in Florida, filed this Current Report on Form 8-K on May 20, 2026. The filing serves as a Regulation FD disclosure regarding the publication of a peer-reviewed preclinical study.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on scientific developments and does not contain financial statements or operational metrics.
Material Changes
The material event reported is the publication of a preclinical study titled "Intracellular copper redox modulation disrupts ROS–Ca²⁺ amplification in an ATP7B-deficient zebrafish model of Wilson's disease" in the journal Advances in Redox Research. The study evaluated the company's candidate, Telomir-1 (Telomir-Zn), in cellular systems and a zebrafish model.
Outlook, Management Commentary, and Risks
- Study Findings: The publication reported reductions in oxidative stress signaling, intracellular calcium dysregulation, hepatic copper accumulation, liver injury biomarkers, and histopathological degeneration. Additionally, the study noted improvements in locomotor performance and survival outcomes in the model.
- Legal Disclaimer: In accordance with General Instruction B.2 of Form 8-K, the information in this report, including the press release, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed methodology and limitations of the preclinical study.
- Confirm the publication status and peer-review process of the article in Advances in Redox Research.
- Review the company's most recent 10-K or 10-Q filings for current financial health, cash runway, and debt obligations, as this 8-K contains no financial data.
- Assess the timeline for potential clinical trials based on these preclinical results.